The arrival of semaglutide, the active ingredient in drugs such as Ozempic and other GLP-1 receptor agonists, changed that expectation. Because of this established role, scientists have often assumed that reducing AgRP activity would be an important part of how GLP-1 drugs produce weight loss. In mice genetically modified to lack AgRP neurons, GLP-1 receptor agonists could no longer sustain the same degree of weight loss. Rather, it indicates that their activity may be necessary within the specific physiological context created by GLP-1 receptor agonism. Subject of Research: The role of AgRP hunger neurons in the weight-lowering effects of GLP-1 receptor agonists.